Evidence map›Paper›PMID 36782220›Full record

ArticleGenome medicine2023

Genomic analysis of the international high-risk clonal lineage Klebsiella pneumoniae sequence type 395.

Elvira R Shaidullina, Michael Schwabe, Thomas Rohde, Valeria V Shapovalova, Marina S Dyachkova, Alina D Matsvay, Yuliya A Savochkina, Andrey A Shelenkov, Yulia V Mikhaylova, Katharina Sydow and 17 more

Abstract read
In one paragraph

Article in Genome medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Carbapenemase-producing hypervirulentJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026
    Article
  9. Article
  10. A Pilot Study ofDiagnostics (Basel, Switzerland) · 2026
    Article
  11. Antibiotic Resistance inAntibiotics (Basel, Switzerland) · 2026
    Review
  12. Article
  13. Genomic surveillance of carbapenem-resistantFrontiers in microbiology · 2026
    Article
  14. Article
  15. Lineage-specific evolution and resistance-virulence divergence inAntimicrobial agents and chemotherapy · 2025
    Article
  16. Potential in-host evolution ofMicrobiology spectrum · 2025
    Article
  17. Cross-border spread of a mosaic resistance (OXA-48) and virulence (aerobactin) plasmid inEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  18. Review
  19. Article
  20. Molecular Epidemiology and In-Depth Characterization ofInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Elvira R Shaidullina *Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia.
Michael Schwabe *Pharmaceutical Microbiology, Institute of Pharmacy, University of Greifswald, Greifswald, Germany.
Thomas RohdePharmaceutical Microbiology, Institute of Pharmacy, University of Greifswald, Greifswald, Germany.
Valeria V ShapovalovaFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency, Moscow, Russia.
Marina S DyachkovaFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency, Moscow, Russia.
Alina D MatsvayFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency, Moscow, Russia.
Yuliya A SavochkinaFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency, Moscow, Russia.
Andrey A ShelenkovCentral Research Institute of Epidemiology, Moscow, Russia.
Yulia V MikhaylovaCentral Research Institute of Epidemiology, Moscow, Russia.
Katharina SydowPharmaceutical Microbiology, Institute of Pharmacy, University of Greifswald, Greifswald, Germany.
François LebretonMultidrug-Resistant Organism Repository and Surveillance Network, Walter Reed Army Institute of Research, Silver Spring, USA.
Evgeny A IdelevichFriedrich Loeffler-Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany.
Stefan E HeidenPharmaceutical Microbiology, Institute of Pharmacy, University of Greifswald, Greifswald, Germany.
Karsten BeckerFriedrich Loeffler-Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany.
Roman S KozlovInstitute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia.
German A ShipulinFederal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency, Moscow, Russia.
Vasiliy G AkimkinCentral Research Institute of Epidemiology, Moscow, Russia.
Michael LalkInstitute of Biochemistry, University of Greifswald, Greifswald, Germany.
Sebastian GuentherPharmaceutical Biology, Institute of Pharmacy, University of Greifswald, Greifswald, Germany.
Andreas E ZautnerInstitute of Medical Microbiology and Hospital Hygiene, Medical Faculty, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
Jürgen A BohnertFriedrich Loeffler-Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany.
Ayslu M MardanovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.
Ruth BouganimDepartment of Internal Medicine A, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel.
Dror MarchaimInfection Control Unit, Shamir (Assaf Harofeh) Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Katharina J HoffInstitute of Mathematics and Computer Science, University of Greifswald, Greifswald, Germany.
Katharina Schaufler *Pharmaceutical Microbiology, Institute of Pharmacy, University of Greifswald, Greifswald, Germany. schaufler@infmed.uni-kiel.de.ORCID 0000-0002-2669-8799
Mikhail V Edelstein *Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKlebsiella pneumoniae, which is frequently associated with hospital- and community-acquired infections, contains multidrug-resistant (MDR), hypervirulent (hv), non-MDR/non-hv as well as convergent representatives. It is known that mostly international high-risk clonal lineages including sequence types (ST) 11, 147, 258, and 307 drive their global spread. ST395, which was first reported in the context of a carbapenemase-associated outbreak in France in 2010, is a less well-characterized, yet emerging clonal lineage.

methodsWe computationally analyzed a large collection of K. pneumoniae ST395 genomes (n = 297) both sequenced in this study and reported previously. By applying multiple bioinformatics tools, we investigated the core-genome phylogeny and evolution of ST395 as well as distribution of accessory genome elements associated with antibiotic resistance and virulence features.

resultsClustering of the core-SNP alignment revealed four major clades with eight smaller subclades. The subclades likely evolved through large chromosomal recombination, which involved different K. pneumoniae donors and affected, inter alia, capsule and lipopolysaccharide antigen biosynthesis regions. Most genomes contained acquired resistance genes to extended-spectrum cephalosporins, carbapenems, and other antibiotic classes carried by multiple plasmid types, and many were positive for hypervirulence markers, including the siderophore aerobactin. The detection of "hybrid" resistance and virulence plasmids suggests the occurrence of the convergent ST395 pathotype.

conclusionsTo the best of our knowledge, this is the first study that investigated a large international collection of K. pneumoniae ST395 genomes and elucidated phylogenetics and detailed genomic characteristics of this emerging high-risk clonal lineage.

Indexed as

beta-LactamasesDrug Resistance, BacterialGenes, BacterialKlebsiella pneumoniaeAnti-Bacterial AgentsCarbapenemsClone CellsGenomicsHumansPlasmidsAnti-Bacterial Agentsbeta-LactamasesCarbapenemsCarbapenem resistanceESBLHypervirulenceKlebsiella pneumoniaeMultidrug-resistancePlasmidRecombinationWhole genome sequencing

Identifiers

PMID36782220
PMCPMC9926764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.